170 related articles for article (PubMed ID: 37226642)
1. KRAS
Cai C; Yao S; Zou Y; Lu H; Chen X; Wang Y; Zheng K; Zhu F; Wang Y; Xiong H; Zhu J
J Cell Mol Med; 2023 Jun; 27(12):1637-1652. PubMed ID: 37226642
[TBL] [Abstract][Full Text] [Related]
2. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
4. Xanthohumol inhibits non-small cell lung cancer via directly targeting T-lymphokine-activated killer cell-originated protein kinase.
Zhao S; Cui J; Cao L; Han K; Ma X; Chen H; Yin S; Zhao C; Ma C; Hu H
Phytother Res; 2023 Jul; 37(7):3057-3068. PubMed ID: 36882184
[TBL] [Abstract][Full Text] [Related]
5. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
6. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
[TBL] [Abstract][Full Text] [Related]
8. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
[No Abstract] [Full Text] [Related]
9. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
10. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.
Zhang Y; Liu L; Pei J; Ren Z; Deng Y; Yu K
Oncogene; 2024 Feb; 43(9):668-681. PubMed ID: 38191673
[TBL] [Abstract][Full Text] [Related]
11. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
12. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
13. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS
Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C
J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747
[TBL] [Abstract][Full Text] [Related]
14. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS
Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y
Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411
[TBL] [Abstract][Full Text] [Related]
16. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
17. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
[TBL] [Abstract][Full Text] [Related]
18. Ganoderma microsporum immunomodulatory protein combined with KRAS
Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
Boeschen M; Kuhn CK; Wirtz H; Seyfarth HJ; Frille A; Lordick F; Hacker UT; Obeck U; Stiller M; Bläker H; von Laffert M
Lung Cancer; 2023 Oct; 184():107361. PubMed ID: 37699269
[TBL] [Abstract][Full Text] [Related]
20. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M
ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
